Egy népességre alapozott eset-kontroll tanulmány a broncho-vaxom alkalmazásáról terhességben

Translated title of the contribution: A population-based case-control study of bronchovaxom use during pregnancy

Zoltán Kazy, E. Czeizel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To study human teratogenic potential of oral broncho-vaxom treatments during pregnancy. Aim: Pair analysis of cases with congenital abnormalities and matched population controls without congenital abnormalities. Patients and method: The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Participants: Of 38.151 pregnant women who had babies without any defects (control group), and 22.865 pregnant women who had newborn infants or fetuses with congenital abnormalities (case group). Results: In the control group 58 (0,15%), while in the case group 22 (0,10%) pregnant women were treated with broncho-vaxom (OR with 95% CI: 0.6, 0.4-1.1). The case-control pair analysis concerning the use of broncho-vaxom during the second-third months of pregnancy did not show any human teratogenic potential in the different groups of congenital abnormalities. The mean gestational age was longer in control infants born to mother with broncho-vaxom treatment during pregnancy compared with the figure of control infants without this treatment (40 ± 1.3 vs. 39.4 ± 2.1, t = 2.28, p = 0.02). Conclusion: Teratogenic risk for congenital abnormalities was not detectable in the children born to women treated with broncho-vaxom during pregnancy. The possible gestational age promoter effect of broncho-vaxom needs further studies.

Original languageHungarian
Pages (from-to)2359-2361
Number of pages3
JournalOrvosi Hetilap
Volume146
Issue number46
Publication statusPublished - 2005

Fingerprint

Case-Control Studies
Pregnancy
Population
Pregnant Women
Gestational Age
Control Groups
Population Control
Broncho-Vaxom
Fetus
Therapeutics
Mothers
Newborn Infant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Egy népességre alapozott eset-kontroll tanulmány a broncho-vaxom alkalmazásáról terhességben. / Kazy, Zoltán; Czeizel, E.

In: Orvosi Hetilap, Vol. 146, No. 46, 2005, p. 2359-2361.

Research output: Contribution to journalArticle

@article{b49627e838ba4c5d90523591aa52dcfa,
title = "Egy n{\'e}pess{\'e}gre alapozott eset-kontroll tanulm{\'a}ny a broncho-vaxom alkalmaz{\'a}s{\'a}r{\'o}l terhess{\'e}gben",
abstract = "Objective: To study human teratogenic potential of oral broncho-vaxom treatments during pregnancy. Aim: Pair analysis of cases with congenital abnormalities and matched population controls without congenital abnormalities. Patients and method: The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Participants: Of 38.151 pregnant women who had babies without any defects (control group), and 22.865 pregnant women who had newborn infants or fetuses with congenital abnormalities (case group). Results: In the control group 58 (0,15{\%}), while in the case group 22 (0,10{\%}) pregnant women were treated with broncho-vaxom (OR with 95{\%} CI: 0.6, 0.4-1.1). The case-control pair analysis concerning the use of broncho-vaxom during the second-third months of pregnancy did not show any human teratogenic potential in the different groups of congenital abnormalities. The mean gestational age was longer in control infants born to mother with broncho-vaxom treatment during pregnancy compared with the figure of control infants without this treatment (40 ± 1.3 vs. 39.4 ± 2.1, t = 2.28, p = 0.02). Conclusion: Teratogenic risk for congenital abnormalities was not detectable in the children born to women treated with broncho-vaxom during pregnancy. The possible gestational age promoter effect of broncho-vaxom needs further studies.",
keywords = "Broncho-vaxom, Case-control pair analysis, Congenital abnormalities, Gestational age birth weight, Human teratogenic potential",
author = "Zolt{\'a}n Kazy and E. Czeizel",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2359--2361",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "46",

}

TY - JOUR

T1 - Egy népességre alapozott eset-kontroll tanulmány a broncho-vaxom alkalmazásáról terhességben

AU - Kazy, Zoltán

AU - Czeizel, E.

PY - 2005

Y1 - 2005

N2 - Objective: To study human teratogenic potential of oral broncho-vaxom treatments during pregnancy. Aim: Pair analysis of cases with congenital abnormalities and matched population controls without congenital abnormalities. Patients and method: The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Participants: Of 38.151 pregnant women who had babies without any defects (control group), and 22.865 pregnant women who had newborn infants or fetuses with congenital abnormalities (case group). Results: In the control group 58 (0,15%), while in the case group 22 (0,10%) pregnant women were treated with broncho-vaxom (OR with 95% CI: 0.6, 0.4-1.1). The case-control pair analysis concerning the use of broncho-vaxom during the second-third months of pregnancy did not show any human teratogenic potential in the different groups of congenital abnormalities. The mean gestational age was longer in control infants born to mother with broncho-vaxom treatment during pregnancy compared with the figure of control infants without this treatment (40 ± 1.3 vs. 39.4 ± 2.1, t = 2.28, p = 0.02). Conclusion: Teratogenic risk for congenital abnormalities was not detectable in the children born to women treated with broncho-vaxom during pregnancy. The possible gestational age promoter effect of broncho-vaxom needs further studies.

AB - Objective: To study human teratogenic potential of oral broncho-vaxom treatments during pregnancy. Aim: Pair analysis of cases with congenital abnormalities and matched population controls without congenital abnormalities. Patients and method: The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Participants: Of 38.151 pregnant women who had babies without any defects (control group), and 22.865 pregnant women who had newborn infants or fetuses with congenital abnormalities (case group). Results: In the control group 58 (0,15%), while in the case group 22 (0,10%) pregnant women were treated with broncho-vaxom (OR with 95% CI: 0.6, 0.4-1.1). The case-control pair analysis concerning the use of broncho-vaxom during the second-third months of pregnancy did not show any human teratogenic potential in the different groups of congenital abnormalities. The mean gestational age was longer in control infants born to mother with broncho-vaxom treatment during pregnancy compared with the figure of control infants without this treatment (40 ± 1.3 vs. 39.4 ± 2.1, t = 2.28, p = 0.02). Conclusion: Teratogenic risk for congenital abnormalities was not detectable in the children born to women treated with broncho-vaxom during pregnancy. The possible gestational age promoter effect of broncho-vaxom needs further studies.

KW - Broncho-vaxom

KW - Case-control pair analysis

KW - Congenital abnormalities

KW - Gestational age birth weight

KW - Human teratogenic potential

UR - http://www.scopus.com/inward/record.url?scp=33644833674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644833674&partnerID=8YFLogxK

M3 - Article

C2 - 16370248

AN - SCOPUS:33644833674

VL - 146

SP - 2359

EP - 2361

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 46

ER -